J. Calnan & Associates, Inc. (JC&A), one of the leading construction management firms in the Northeast specializing in world-class pre-construction services and challenging construction projects, recently completed the corporate headquarters for Dicerna™ Pharmaceuticals, Inc, a developer of investigational ribonucleic acid interference (RNAi) therapeutics.
Together with R.E. Dinneen Architects and AHA Engineers, JC&A transformed 80,000 square feet in Lexington for Dicerna. The team upgraded Dicerna’s existing lobby and atrium, and significantly upgraded existing office and laboratory spaces. The team added a new chemistry lab, a commercial kitchen, and a state-of-the-art fitness center. Exterior highlights include a staircase that allows direct access from all three floors to the new, expansive back patio, as well as a new front patio and trellis.
“We are proud to be part of Dicerna’s successful transition to Lexington,” said Greg Lewis, project executive, life sciences at J. Calnan & Associates. “In the end, it’s all about improving patients’ lives, and this new headquarters will allow them to further advance their therapies.”
“At Dicerna, our mission is to leverage our proprietary GalXC™ RNAi technology platform to develop new therapies for patients with rare and common diseases that have a genetic component. There is an urgency to the work that we do, and the recent, rapid expansion to our new Lexington facility will provide our growing team with additional infrastructure and capacity to deliver new medicines to patients,” said Douglas Fambrough, Ph.D., president and chief executive officer of Dicerna.
JC&A builds for the world’s top Life Sciences companies. Our specialized Life Sciences team has extensive experience working in challenging cGMP environments including occupied spaces, clean rooms, operational vivariums and labs. We also have worked for various user groups with strict security requirements and aggressive schedules. Some of these groups include Sanofi Genzyme, Biogen, Parexel International, Takeda, Acceleron and MassBio.
